Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 546 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Lupus Erythematosus (Disorder) Clear all
Completed Phase 2 Interventional

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

NCT00657189
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus
Interventions
MEDI-545, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
22
States / cities
Anniston, Alabama • Huntington Beach, California • Upland, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Fontana, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

NCT02338999
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
PET/CT, Pioglitazone, Placebo
Radiation · Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)

NCT00418587
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cholecalciferol
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 9, 2026, 4:31 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ianalumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT05097989
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Zostavax in Systemic Lupus Erythematosus

NCT01474720
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Zostavax vaccine
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 9, 2026, 4:31 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • La Jolla, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

NCT00198068
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting Phase 3 Interventional

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT05799378
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Withdrawn Phase 1Phase 2 Interventional

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

NCT06935474
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
C-CAR168
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting Phase 4 Interventional

Dapagliflozin in Active Lupus Nephritis

NCT07323524
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Active, not recruiting Phase 3 Interventional

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Medi-546, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
33
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

NCT02535689
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

NCT06013995
View directory record Official record
Conditions
Lupus
Interventions
BMS-986326, Placebo for BMS-986326
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Diego, California • Clearwater, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting No phase listed Observational

CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry

NCT06804057
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Blood Collection
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT06897930
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
AZD0120, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
No Longer Available No phase listed Expanded access

Compassionate Use for Subcutaneous (SC) Belimumab

NCT03125486
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SC belimumab 200 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

NCT01972568
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT03724916
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

NCT00050713
View directory record Official record
Conditions
Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

NCT01085097
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 9, 2026, 4:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus

NCT00042523
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 4:31 PM EDT